Key Points
- Chair Michel Demaré purchased 2,500 AstraZeneca shares for approximately £303,000 at an average price of £121.21, potentially signaling insider confidence.
- AstraZeneca and Daiichi Sankyo reported that Enhertu extended progression-free survival by six months in a first-line lung cancer trial, supporting the oncology partnership’s prospects.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and £150 average price target, but AstraZeneca faces pressure after its Etcamah combination failed to meet the primary endpoint in the Phase III SERENA-4 trial.
AstraZeneca PLC (LON:AZN - Get Free Report) insider Michel Demare acquired 2,500 shares of the company's stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of £121.21 per share, with a total value of £303,025.
AstraZeneca Stock Down 0.3%
LON:AZN opened at £121.16 on Wednesday. The stock's fifty day moving average price is £122.39 and its two-hundred day moving average price is £134.90. AstraZeneca PLC has a 52-week low of £107.84 and a 52-week high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market cap of £187.91 billion, a price-to-earnings ratio of 18.14, a P/E/G ratio of 0.86 and a beta of 0.20.
Key Headlines Impacting AstraZeneca
Here are the key news stories impacting AstraZeneca this week:
- Positive Sentiment: Chair Michel Demaré purchased 2,500 AstraZeneca shares for approximately £303,000 at an average price of £121.21. The transaction may be viewed as a sign of confidence from a senior insider. AstraZeneca Chair Michel Demaré Buys Additional Shares in the Company
- Positive Sentiment: AstraZeneca and Daiichi Sankyo reported that Enhertu improved progression-free survival by six months in a first-line trial for HER2-mutant non-small-cell lung cancer. The result supports the commercial and clinical potential of the companies’ oncology partnership. AstraZeneca's Enhertu Improves PFS By 6 Months
- Neutral Sentiment: Deutsche Bank upgraded AstraZeneca to “hold,” while maintaining a £117 price target. The change is modestly more favorable in rating terms but still indicates limited near-term upside at the bank’s valuation. Deutsche Bank Upgrades AstraZeneca to Hold
- Neutral Sentiment: Berenberg retained a “buy” rating but reduced its price target from £160 to £150, suggesting continued long-term confidence alongside more cautious expectations.
- Negative Sentiment: AstraZeneca’s Etcamah combination failed to meet the primary endpoint in the Phase III SERENA-4 trial. The setback could weaken expectations for the treatment’s future revenue contribution and is likely the most significant near-term pressure on the shares. AstraZeneca SERENA-4 Trial Fails to Meet Primary Objective
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a £117 price target on shares of AstraZeneca in a research note on Tuesday. Royal Bank Of Canada reissued an "outperform" rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Berenberg Bank cut their target price on shares of AstraZeneca from £160 to £150 and set a "buy" rating on the stock in a research report on Tuesday. Jefferies Financial Group reaffirmed a "buy" rating and issued a £175 target price on shares of AstraZeneca in a research note on Wednesday, September 9th. Finally, Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average price target of £150.
Get Our Latest Analysis on AZN
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
